Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) CEO Gilmore O’neill sold 21,164 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $2.42, for a total value of $51,216.88. Following the sale, the chief executive officer directly owned 265,592 shares of the company’s stock, valued at approximately $642,732.64. This trade represents a 7.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Gilmore Neil O’neill also recently made the following trade(s):
- On Thursday, September 3rd, Gilmore O’neill sold 5,124 shares of Editas Medicine stock. The stock was sold at an average price of $3.04, for a total value of $15,576.96.
Editas Medicine Stock Performance
NASDAQ EDIT opened at $2.17 on Monday. Editas Medicine, Inc. has a one year low of $1.66 and a one year high of $3.94. The company’s 50 day moving average price is $2.63 and its 200 day moving average price is $2.69. The firm has a market capitalization of $334.92 million, a price-to-earnings ratio of -3.50 and a beta of 2.08.
Editas Medicine (NASDAQ:EDIT – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $10.37 million during the quarter, compared to the consensus estimate of $4.46 million. Editas Medicine had a negative return on equity of 130.43% and a negative net margin of 144.95%. Sell-side analysts forecast that Editas Medicine, Inc. will post -0.79 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in Editas Medicine during the second quarter worth approximately $31,000. Private Advisor Group LLC bought a new stake in shares of Editas Medicine in the 3rd quarter worth $31,000. R Squared Ltd acquired a new stake in shares of Editas Medicine in the third quarter valued at $32,000. Pallas Capital Advisors LLC bought a new position in Editas Medicine during the second quarter valued at about $38,000. Finally, State of Wyoming bought a new stake in Editas Medicine in the first quarter worth about $43,000. Institutional investors own 71.90% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on EDIT. Wells Fargo & Company upgraded Editas Medicine from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $4.00 to $6.00 in a report on Thursday, October 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Editas Medicine in a research note on Wednesday, November 4th. Wall Street Zen raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Ladenburg Thalmann & Co. Inc. began coverage on shares of Editas Medicine in a research report on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Guggenheim upgraded Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Wednesday, September 23rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Editas Medicine has an average rating of “Moderate Buy” and an average target price of $5.83.
Editas Medicine Company Profile
Editas Medicine, Inc. is a biotechnology company developing genome-editing medicines for people with serious diseases. Its research uses CRISPR-based technologies, including CRISPR-Cas9 and Cas12a, to make targeted changes to DNA. Founded in 2013 and based in Cambridge, Massachusetts, the company conducts research and clinical development of potential treatments for genetic disorders. Its work has included approaches designed to edit genes in a patient’s cells, either outside the body or directly within the body.
Recommended Stories
- Five stocks we like better than Editas Medicine
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
